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Summary
Feyaerts et al. demonstrate that an integrated analysis of plasma and single-cell
proteomics differentiates COVID-19 severity and reveals severity-specific biological
signatures associated with the dysregulation of the JAK/STAT, MAPK/mTOR, and NF-κB
immune signaling networks and the mobilization of the renin-angiotensin and hemostasis
systems.

Abstract
The biological determinants of the wide spectrum of COVID-19 clinical manifestations are
not fully understood. Here, over 1400 plasma proteins and 2600 single-cell immune
features comprising cell phenotype, basal signaling activity, and signaling responses to
inflammatory ligands were assessed in peripheral blood from patients with mild,
moderate, and severe COVID-19, at the time of diagnosis. Using an integrated
computational approach to analyze the combined plasma and single-cell proteomic data,
we identified and independently validated a multivariate model classifying COVID-19
severity (multi-class AUCtraining = 0.799, p-value = 4.2e-6; multi-class AUCvalidation = 0.773,
p-value = 7.7e-6). Features of this high-dimensional model recapitulated recent COVID19 related observations of immune perturbations, and revealed novel biological
signatures of severity, including the mobilization of elements of the renin-angiotensin
system and primary hemostasis, as well as dysregulation of JAK/STAT, MAPK/mTOR,
and NF-κB immune signaling networks. These results provide a set of early determinants
of COVID-19 severity that may point to therapeutic targets for the prevention of COVID19 progression.
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Introduction
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic, caused by the novel and
highly contagious Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (Lu
et al., 2020b) has affected more than 105 million patients worldwide as of early 2021
(Dong et al., 2020). A wide range of clinical manifestations exists for COVID-19, which
require different intervention strategies. While the majority of patients with COVID-19
experience mild or asymptomatic infections, nearly 20% of patients develop severe
disease requiring hospitalization (Wu and McGoogan, 2020). A substantial portion (8%30%) of those hospitalized patients ultimately succumbs to the disease, leading to a
devastating global tally of COVID-19 fatalities (CDC, 2021; Horwitz et al., 2021; Piroth et
al., 2020; Rosenthal et al., 2020; Wu and McGoogan, 2020).
Varying outcomes for COVID-19 depend on a set of risk factors and the interplay
between viral replication, tissue damage, as well as a balance of beneficial and
detrimental host immune responses. Several studies have provided evidence for
profoundly altered immune responses caused by SARS-CoV-2 infection, including
sustained functional changes in circulating immune cells. Lymphopenia (Cao, 2020;
Rodriguez et al., 2020), increased inflammatory plasma cytokine levels (Del Valle et al.,
2020), dysregulated innate immune cell function (Arunachalam et al., 2020; SchulteSchrepping et al., 2020; Wilk et al., 2020), and abnormal T cell activation (Mathew et al.,
2020) have been observed, particularly in hospitalized patients with severe COVID-19.
However, prior studies have primarily focused on patients with severe COVID-19, while
fewer studies have included non-hospitalized patients with mild and moderate COVID-19
(Chevrier et al., 2021; Silvin et al., 2020; Su et al., 2020). In addition, while prior studies
have reported on the distribution, phenotype, and transcriptional profile of peripheral
immune cells, how SARS-CoV-2 infection alters immune cell signaling responses to
inflammatory challenges (or immune signaling networks) has not been determined. As
such, the immunological mechanisms that differentiate patients with mild, moderate, and
severe COVID-19 are poorly understood. Unraveling the underlying immune
pathogenesis across the spectrum of COVID-19 presentations is important to both
understand the drivers of disease severity as well as to identify clinically relevant
biomarkers that can inform therapeutic interventions.
High-dimensional mass cytometry immunoassays are uniquely adapted to the
analysis of immune cell signaling networks as multiple intracellular signaling events (e.g.
post-translational protein modifications) are simultaneously quantified in precisely
phenotyped immune cells, at baseline and in response to ex vivo stimulations. The
approach has previously enabled the identification of clinically-relevant biological
signatures predictive of patient outcomes in several clinical contexts, including infection,
malignancies, stroke, and traumatic injury (Ganio et al., 2020; Gaudilliere et al., 2014;
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Good et al., 2018; Irish and Doxie, 2014; Myklebust et al., 2017; Rahil et al., 2020; Tsai
et al., 2019).
In this study, we combined the mass-cytometry analysis of immune cell signaling
responses with the high-content proteomic analysis of plasma analytes in blood samples
from patients with mild, moderate, and severe COVID-19 to identify biological signatures
that demarcate COVID-19 clinical manifestations. The integrated single-cell and plasma
proteomic analysis allowed including an additional dimension in the characterization of
immune signaling networks by accounting for the plasma environment of circulating
immune cells.
Results
Combined plasma and single-cell proteomic analysis of peripheral blood samples from
patients with mild, moderate, and severe COVID-19
97 SARS-CoV-2 positive patients with mild, moderate or severe COVID-19 were enrolled
in this study at Stanford University Medical Center in California, USA (Figure 1A). Patient
characteristics can be found in Table 1. COVID-19 severity was determined using
previously defined clinical criteria ((Chen et al., 2020); see Methods). For each patient a
peripheral blood sample was collected at the time of COVID-19 diagnosis. Samples from
SARS-CoV-2 positive patients were examined alongside those from 40 healthy controls
collected at Stanford in 2019, before the detection of SARS-CoV-2 in the geographic
region. Blood samples were used to isolate both plasma and peripheral blood
mononuclear cells (PBMC). PBMC were stimulated ex vivo to trigger pathogen sensing
and cytokine signaling response pathways in innate and adaptive immune cells relevant
during infection (TLR4 stimulant LPS and TLR7/8 agonist CL097; IFN𝛼, IL-2, IL-4, and
IL-6 cytokine cocktail; and cell stimulation cocktail consisting of phorbol 12-myristate 13acetate (PMA) and Ionomycin (I) (PI)) (Figure 1B). The frequencies of 44 manually-gated
immune cell subsets representing major circulating innate and adaptive immune cells
were determined using a 42-parameter single-cell phospho-mass cytometry
immunoassay (Figure S1). For each immune cell subset, the frequency was determined,
alongside baseline signaling activity (unstimulated condition) and signaling response
capacity of cells to ex vivo stimulation with inflammatory reagents, which were measured
by examining the phosphorylation state of 15 intracellular signaling proteins. The mass
cytometry analysis resulted in a total of 2662 immune cell response features per PBMC
sample. To complement this single-cell analysis, 1472 circulating plasma proteins were
measured using the proximity extension assay (PEA) platform from Olink Proteomics.
Five mass cytometry (cell frequency, baseline signaling, IFN𝛼/IL-2/IL-4/IL-6 signaling
response, LPS/CL097 signaling response, and PI signaling response) and one plasma
proteomic data layer(s) were collected, resulting in six data layers in total. Correlation
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networks demonstrate the existence of strong inter- and intra-layer correlations between
features (Figure 1C-D).

Figure 1 - Combined plasma and single-cell proteomic profiling of patients with mild, moderate, and severe
COVID-19.
A Patients with mild (50), moderate (21), and severe (26) COVID-19 were examined together with 40 healthy controls.
B Schematic representation of the experimental workflow. Plasma proteins were measured using the Olink Explore
1536 assay, while PBMC were stimulated with either LPS+CL097, IFN𝛼+IL-2+IL-4+IL-6, PMA+ionomycin (PI), or left
unstimulated (Unstim) before barcoding, antibody staining, and analysis by single-cell mass cytometry. C-D Correlation
networks of single-cell mass cytometry and proteome dataset. Each node represents a feature, with edges representing
the correlation between features (cor > 0.9). Node size reflects -𝑙𝑜𝑔10 of p-value of the correlation with severity
(Spearman) and node color represents the different data layers. E Bivariate scatterplot of patients with COVID-19 and
healthy controls plotted along factors 3 and 10 identified by multi-omic factor analysis (MOFA; see Figure S2).
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Table 1 – Patient characteristics. Data are shown as a number and a percentage. Age
is reported in median years (minimum to maximum).
Total (N =137)
Control (N=40)
COVID+ (N=97)
Age

45 (19-78)

Sex

N

%

N

%

N

%

M

59

43.07

16

40

43

44.33

F

78

56.93

24

60

54

55.67

N

%

N

%

N

%

Asian

34

24.82

11

27.5

23

23.71

Hispanic/Latino

33

24.09

0

0

33

34.02

Caucasian

49

35.77

15

37.5

34

35.05

Black

6

4.38

1

2.5

5

5.15

Multiracial

5

3.65

3

7.5

2

2.06

Middle Eastern

1

0.73

1

2.5

0

0

Not reported

9

6.57

9

22.5

0

0

Disease Status

N

%

N

%

N

%

40

29.2

40

100

0

0

2

1.46

0

0

2

2.06

Mild

48

35.04

0

0

48

49.48

Moderate

21

15.33

0

0

21

21.65

Severe

26

18.98

0

0

26

26.8

N

%

N

%

N

%

13

9.49

0

0

13

13.4

5

3.65

1

2.5

4

4.12

No

96

70.07

32

80

64

65.98

Not reported

23

16.79

7

17.5

16

16.5

N

%

N

%

N

%

Yes

24

17.52

4

10

20

20.62

No

85

62.04

29

72.5

56

57.73

Not reported

28

20.44

7

17.5

21

21.65

N

%

N

%

N

%

15

10.95

5

12.5

10

10.31

115

83.94

28

70

87

89.69

Not reported

7

5.11

7

17.5

0

0

Obesity

N

%

N

%

N

%

Yes

18

13.14

0

0

18

18.6

No
Not reported

89
30

64.96
21.9

33
7

82.5
17.5

56

57.7

23

23.7

Ethnicity

Healthy
Asymptomatic

48 (23-73)

44 (19-78)

Comorbidities
Diabetes
Yes
Prediabetic

Asthma

CV Condition
Yes
No
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To understand the relationships between the different data layers and COVID-19
severity, we first applied unsupervised dimensionality reduction with multi-omics factor
analysis (MOFA; (Argelaguet et al., 2018)), which infers a set of factors that capture
shared sources of variability across different datasets. We supplied all six data layers for
the analysis, resulting in a MOFA model with 17 factors (Figure S2A). Both single-cell
immune response (baseline signaling and signaling response to IFN𝛼/IL-2/IL-4/IL-6 and
LPS/CL097; factor 10) and plasma proteome (factor 3) data contributed strongly to the
variance observed in our samples (Figure S2B) and were significantly associated with
COVID-19 severity (Figure S2C). A gradient with increasing disease severity across
factors 3 and 10 (Figure 1E) was also observed, suggesting that single-cell immune
response and plasma proteome data both contain clinically important biological events.
The results prompted us to perform an integrated analysis to determine whether a
classifier of COVID-19 severity could be derived from the combined plasma and singlecell proteomics data.
Integrated modeling of plasma and single-cell proteome differentiates COVID-19 severity
A high-dimensional computational analysis pipeline was applied to train and
independently validate (training cohort: n=74; 25 control, 20 mild, 10 moderate, and 19
severe patients; validation cohort: n=63; 15 control, 30 mild, 11 moderate, and 7 severe
patients) an integrated model of COVID-19 severity based on the combined proteomic
and single-cell immune response data (Ghaemi et al., 2019). In this approach, the six
data layers were considered separately and a two-step process was used to combine
these data layers in a multi-omic fashion (Figure 2A). Cross-validated multivariate Least
Absolute Shrinkage and Selection Operator (LASSO) linear regression models
(Tibshirani, 1996) were first trained for each individual data layer of the training cohort,
with disease severity used as a ranked order variable (i.e., control classed as 1 to severe
classed as 4), and second, the individual prediction models were integrated into a single
model by stacked generalization (SG) (Ghaemi et al., 2019) (Figure 2A). The second
step uses the estimations of disease severity of each LASSO model as predictors for a
constrained regression model.
The analysis identified a predictive SG model (“severity model”) that classified
COVID-19 severity categories at time of sampling for patients in the training cohort (R =
0.61, p-value = 4.2e-6, n=74). The generalizability of the severity model was
independently tested in patients from the validation cohort (R = 0.69, p-value = 7.7e-6,
n=63) (Figure 2B-C). The contribution of individual data layers to the overall severity
model was highest for the plasma proteome and lowest for the signaling responses to
LPS/CL097 stimulation, according to severity model coefficients (Table S1).
To estimate the performance of the severity model, a multi-class area under the
curve receiver operating characteristic (ROC) analysis was performed for the training and
validation cohort (Figure 2D-E). The multi-class ROC analysis showed that the severity
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model performed well at classifying patients across disease severity categories (multiclass AUCtraining = 0.799; multi-class AUCvalidation = 0.773). The most accurate classification
was achieved when classifying severe patients from the other patient groups (Table S2).
Results from the severity model indicate that mild, moderate, and severe COVID19 manifestations can be differentiated from the measurement of plasma proteins and
single-cell immune signaling events in patient’s peripheral blood. A confounder analysis
further showed that the severity model remained significant when accounting for clinical
or demographic variables that have previously been associated with COVID-19 severity,
including age, sex, BMI, and time between symptom onset and blood collection (Table
S3).

Figure 2 - Integrated modeling of plasma and single-cell proteomic events categorizes COVID-19 severity
A Integration of all six data layers (proteome, frequency, baseline signaling, LPS/CL097 signaling response, IFN𝛼/IL2/IL-4/IL-6 signaling response, and PI signaling response) using a stacked generalization (SG) method. B-C Outcome
of predicted vs true disease severity derived from SG model for the B training (R = 0.61, p-value = 4.2e-6, n = 74) and
C validation cohort (R = 0.69, p-value = 7.7e-6, n = 73). D-E Multi-class area under the curve receiver operating
characteristic (ROC) analysis of D the training (AUC = 0.799, n = 74) and E validation (AUC = 0.773, n = 73) severity
model (see Table S2 for individual AUCs). 1 = control, 2 = mild, 3 = moderate, and 4 = severe.
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Biological signatures of COVID-19 severity
To facilitate the biological interpretation of the high-dimensional severity model and to
identify potential biomarker targets, the contribution of individual plasma and single-cell
proteomic features to the severity model performance was quantified by measuring
repeated selection during a 1,000-iteration bootstrap procedure (Figure 3A; (Bach, 2008;
Chatterjee and Lahiri, 2011)). We examined in detail the set of features that were within
the top 10% selected by the bootstrap procedure, and that thus contributed strongly to
the overall model (Figure 3B-C and supplemental data file S1). Single-cell (Figure 3B)
and plasma (Figure 3C) proteomic features were visualized with two correlation
networks, highlighting the interconnectivity of the proteomic datasets (edges), and the
correlation between individual features and COVID-19 severity (node size/color).
Features within the top 10% of bootstrap selection segregated into correlated
communities. Single-cell immune response features were annotated according to the
cellular attribute (immune cell frequency or signaling response) most commonly
represented within each community (Figure 3B), while plasma proteomic features were
annotated by protein name (Figure 3C). These communities of informative features are
discussed below in relation to disease severity.

Figure 3 - An iterative bootstrapping method identifies robust informative features for the differentiation of
mild, moderate, and severe COVID-19.
A Workflow of the iterative bootstrap method used to identify informative features in the six data layers of the severity
model. A LASSO regression model was run 1,000 times on random sub-samples with replacement for each data layer,
Xi, then the number of times an individual feature was selected in one of the bootstrap iterations was counted and the
features were ranked according to the frequency of selection in the bootstrap models. B-C Correlation network depicting
single-cell (B) or plasma (C) proteomic features. Edges represent the correlation between features (Spearman cor >
0.9). Blue/orange nodes highlight positive/negative correlation with disease severity. Node size reflects -𝑙𝑜𝑔10 of p-
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value (Spearman). Communities containing the bootstrap-selected informative single-cell (B) or plasma (C) proteomic
features are highlighted and annotated.

Cell frequency features prominent in the correlation network and contributing to
the severity model revealed changes in immune cell distribution that are reminiscent of
recent immunophenotyping studies in patients with severe COVID-19. For instance, in
our study and prior reports, plasmacytoid dendritic cells (pDC) and CD161+CD8+ T cell
frequencies were negatively correlated, while Ki67 +CD8+ T cell and granulocyte
frequencies were positively correlated with COVID-19 severity (Arunachalam et al., 2020;
Chevrier et al., 2021; Kuri-Cervantes et al., 2020; Mathew et al., 2020; Parrot et al., 2020)
(Figure 4A). Furthermore, a positive correlation of plasmablast frequency with severity
was evident in our data, complementing prior reports (Kuri-Cervantes et al., 2020;
Mathew et al., 2020) (Figure S3A).
Assays examining baseline and stimulation dependent cell signaling markers
revealed alterations in cell states associated with varying disease severity. A negative
correlation was observed between baseline signaling in CD8+ T cell subsets and NKT
cells, and COVID-19 severity, notably for the phosphorylated (p) S6, total IkB𝛼, and
pCREB signals (Figure 4B and S3B). Negative correlations with COVID-19 severity were
also observed for the p4EBP1 and total IkB𝛼 signals at baseline in granulocytes, while
granulocyte pERK1/2 signal at baseline was positively correlated with disease severity
(Figure S3B). Overall, this data suggests that alterations in immune cell signaling
markers at baseline exist between COVID-19 severity categories. In particular, baseline
signaling activities of key elements of the mTOR, MAPK, and NF-κB pathway (pS6,
pERK1/2, pCREB, and total IkB𝛼) were diminished with increasing disease severity in
immune cell populations that play important roles in the defense against viral pathogens,
such as CD8+ T, NKT, and granulocyte cell subsets.
Additionally, immune cell signaling responses to PI stimulation were largely
diminished with increasing disease severity, especially for innate immune cell
populations. Specifically, PI-stimulated signaling responses in granulocytes (pS6,
pERK1/2, and pP38), mDCs (pERK1/2 and pSTAT3), and CD56 brightCD16- NK cells
(pP38) were negatively correlated with disease severity (Figure 4C and S3C). Negative
correlations with disease severity were also observed for the pSTAT3 signal in Treg and
pMAPKAPK2 signal in CD161+ CD8+ T cells in response to PI stimulation (Figure 4C and
S3C). Decreased responsiveness to PI stimulation may be an indication of reduced
effector function of circulating innate and adaptive immune cells during severe COVID19, driven by cell-intrinsic effects and/or changes in cytokines and other modulating
factors present in the circulation.
For immune cell signaling responses to IFN𝛼/IL-2/IL-4/IL-6 stimulation, we also
observed a negative correlation with disease severity for the pSTAT4/5/6 signals in both
adaptive and innate immune cells (Figure 4D and S3D), suggestive of an impaired
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signaling response to interferon and cytokines in those individuals with more severe
COVID-19. Indeed, others have also observed an impaired type I interferon activity in
peripheral immune cells of patients critically ill with COVID-19, shown by downregulation
of interferon-stimulated genes upon whole blood IFN𝛼 stimulation (Hadjadj et al., 2020).
Among the most robust plasma proteomic features used by the severity model
were several features that positively correlated with disease severity and which
overlapped with prior descriptions of the cytokine storm syndrome described in patients
with severe COVID-19 (Cao, 2020). For instance, plasma levels of the cytokines IFNɣ,
IL-1β, and IL-33, showed a positive correlation with disease severity (Figure 4E). IL-6,
one of the first plasma cytokines recognized as elevated during COVID-19 (Ruan et al.,
2020), also exhibited a positive correlation with disease severity in our cohort (Figure
S4). Although this feature contributed to the severity model, it ranked well below the top
10% of bootstrap selected informative features (see supplemental data file S1). A
similar positive correlation was observed for lung-related proteins in circulation, such as
pulmonary surfactant-associated protein A2 (SFTPA2) and Cathepsin H (CTSH), which
are involved in surfactant homeostasis (Figure S4) (Buhling et al., 2011; Thorenoor et
al., 2018).
Angiotensin-converting enzyme 2 (ACE2) is used as a viral entry receptor by
SARS-CoV-2 and is released from the epithelial cell surface upon viral binding (Mortaz et
al., 2020). ACE2 ranked within the top 10% of informative features, and levels showed a
positive correlation with severity (Figure S4). The severity model also identified the
protease MME (neprilysin), another key player of the Renin-Angiotensin System (RAS)
(Chappell, 2019), as a positive correlate of COVID-19 severity (Figure S4). MME is also
implicated in neutrophil degranulation (Didangelos, 2020) and our list of informative model
features contained multiple other proteins involved in neutrophil degranulation (protein
pathway identified by Reactome, see methods; Reactome gene set identifier R-HSA6798695.2; Figure S5A), which were mainly positively correlated with severity as well.
This dysregulation of neutrophil degranulation in severe patients is in agreement with
recent plasma proteome findings (Overmyer et al., 2020).
Our analysis revealed tyrosine-protein kinase Mer (MERTK) as the most robust
feature in the proteome dataset contributing to the severity model (supplemental data
file S1). Levels of MERTK, an immunosuppressive tyrosine kinase receptor (Lemke and
Silverman, 2020), were positively correlated with disease severity (Figure 4E). MERTK
is found on the surface of macrophages where it mediates phagocytosis of apoptotic cells
(Cai et al., 2018). Activation of MERTK has an immunosuppressive effect by
downregulating the production of cytokines and type I interferons (Cai et al., 2018; Lemke
and Silverman, 2020). Increased MERTK shedding could result in reduced surface
expression and loss of MERTK signaling (Sather et al., 2007), which could play a central
role in the hyper inflammation observed in severe COVID-19. MERTK also plays a role in
platelet aggregation (Sather et al., 2007) and endothelial barrier integrity (Li et al., 2019).
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Plasma levels of several other proteins involved in primary hemostasis (Reactome gene
set identifier R-HSA-109582) were found to be informative in our model of disease
severity (Figure S5B), with the majority of them displaying positive correlations with
disease severity.
In summary, informative features of the severity model revealed biological
signatures that progressed from mild to moderate and severe COVID-19. Salient
characteristics of this biological progression included cellular elements of immune
signaling networks implicated in defensive immunity against viral pathogens (such as the
progressive dampening of NF-κB, MAPK/mTOR, and JAK/STAT signaling in multiple
innate and adaptive immune cell subsets) and sentinel proteomic pathways involved in
lung and RAS homeostasis, primary hemostasis, neutrophil degranulation, and
inflammation.
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Figure 4 - Severity model features reveal biological signatures that demarcate patients with mild, moderate,
and severe COVID-19.
Boxplots, classified by disease severity, showing features informative to the model, including the correlation of the
feature with disease severity (Spearman coefficient). A Frequency features are shown as a percentage of mononuclear
cells. Granulocytes are shown as a percentage of singlets. pDC and granulocyte frequency are plotted on a log-scale.
B Immune cell signaling at baseline (arcsinh transformed values; see methods). C Immune cell signaling response to
PI stimulation is reported as the arcsinh transformed ratio over the baseline signaling response (see methods). D
Immune cell signaling responses to IFN𝛼/IL-2/IL-4/IL-6 (IFN/IL) stimulation are reported as the arcsinh transformed
ratio over the baseline signaling response (see methods). E Plasma protein levels are reported as the normalized
protein expression, an arbitrary unit provided by the Olink assay. Tmem = memory T cell; MERTK = tyrosine-protein
kinase Mer.
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Discussion
This study combined high-content plasma proteomics with the single-cell analysis of
immune signaling responses to identify biological determinants of severity across the
spectrum of COVID-19 manifestations. Using a two-step analytical approach that
accounts for the dimensionality of different data layers, we built and independently
validated an integrated model that classifies COVID-19 severity. The biological
underpinnings of the severity model consisted of co-regulated plasma and single-cell
proteomic elements that progressed with COVID-19 severity, including the inflammatory
cytokine response to SARS-CoV-2, the mobilization of the Renin-Angiotensin (RAS) and
primary hemostasis systems, and the dysregulation of the JAK/STAT, NF-κB and
MAPK/mTOR immune signaling responses. The identification of biological signatures
progressing with COVID-19 severity provides a set of sentinel events detectable in the
early phase of infection that may be targeted therapeutically for the prevention of severe
COVID-19.
The ongoing pandemic has fueled major research efforts towards understanding
the host immune response against SARS-CoV-2 infection (Arunachalam et al., 2020;
Cao, 2020; Del Valle et al., 2020; Mathew et al., 2020; Schulte-Schrepping et al., 2020;
Wilk et al., 2020). Previous efforts have been particularly focused on hospitalized patients
with severe COVID-19, which, while of paramount importance, excludes the majority of
SARS-CoV-2-infected patients who suffer from mild or moderate COVID-19 and do not
require hospitalization. The comparative analysis of samples from patients with mild,
moderate, and severe disease afforded a more exhaustive characterization of immune
responses related to COVID-19 severity. Our approach dovetails with prior studies
identifying an immunological shift distinguishing the spectrum of COVID-19 infection
states (Chevrier et al., 2021; Su et al., 2020). Consistent with our results, this switch
included an increase in inflammation, the emergence of CD4 and CD8 T cells with a
proliferative-exhausted phenotype, and a distinct activated myeloid signature (Chevrier
et al., 2021; Su et al., 2020). In previous work, immune cell function and responses are
indirectly inferred through either phenotype or baseline single-cell mRNA transcriptomics
changes, while our approach provided a direct assessment of baseline intracellular
signaling responses of multiple immune cell subsets as well as their capacity to respond
to inflammatory stimulation.
Two major biological signatures associated with the progression from mild to
moderate and severe disease emerged from our integrated analysis: 1) the dampening
of NF-κB, MAPK/mTOR and JAK/STAT intracellular signaling responses in multiple
innate and adaptive immune cell subsets; and 2) the mobilization of a proteomic network
enriched for elements of the RAS, lung homeostasis and hemostasis pathways, alongside
canonical elements of the cytokine storm signature of severe COVID-19.
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Several of the features informative to our severity model resonate with previous
findings in patients suffering from severe COVID-19. For example, plasma levels of
cytokines such as IFNɣ, IL-1β, IL-33, and IL-6 increased with increasing severity,
consistent with the cytokine storm observed in severe patients with COVID-19 (Cao,
2020), and with circulating IL-33 levels as a potential indicator of damaged lung tissue
(Liew et al., 2010; Martin and Martin, 2016; Zizzo and Cohen, 2020). In addition, changing
frequencies of circulating immune cells also aligned with prior reports in severe patients
(Arunachalam et al., 2020; Kuri-Cervantes et al., 2020; Mathew et al., 2020; Parrot et al.,
2020; Wilk et al., 2020). Interestingly, an increased percentage of granulocytes was
observed in the PBMC fraction of patients with severe COVID-19 (Chevrier et al., 2021;
Schulte-Schrepping et al., 2020; Wilk et al., 2020). Low-density granulocytes also appear
in the PBMC fraction of patients with inflammatory diseases and severe infection (Hassani
et al., 2020; Silvestre-Roig et al., 2019).
The functional analysis of intracellular signaling events in this study revealed
intriguing new biology associated with COVID-19 severity, notably with respect to immune
cell responses to inflammatory ligands. The aforementioned low-density granulocytes can
display dysfunctional immune responses (Hassani et al., 2020; Silvestre-Roig et al.,
2019), which dovetails with our observation of decreased immune cell signaling response
by the granulocytes present in the PBMC fraction of patients with severe disease. In
addition, in agreement with Overmyer et al. (Overmyer et al., 2020), increasing plasma
levels of several proteins involved in neutrophil degranulation were correlated with
disease severity. Excessive release of granules can result in tissue damage and is a
feature of acute lung injury and septic shock (Lacy, 2006). In addition to granulocytes,
other cell types such as mDCs, NK cells, NKT cells, Tregs, and CD4 and CD8 T cells also
showed an inverse relationship between capacity to respond to cytokine stimulation and
disease severity, suggestive of overall diminished effector functions of circulating innate
and adaptive immune cells with increasing severity. Indeed, others have shown
decreased functional responses and exhausted phenotypes in peripheral innate and
adaptive immune cells in severe patients as well (Arunachalam et al., 2020; Hadjadj et
al., 2020; Kusnadi et al., 2021; Remy et al., 2020b; Wilk et al., 2020). As such, restoring
the effector responses of circulating immune cells by immune potentiators (e.g. immune
checkpoint inhibitors) to enhance host immunity while simultaneously controlling the
cytokine storm (e.g. corticosteroids) may be beneficial in preventing severe disease and
overcoming infection (Florindo et al., 2020; Remy et al., 2020a; Tang et al., 2020).
In addition to dysregulated immune signaling responses, the examination of the
severity model features revealed several key proteomic pathways that were mobilized
with disease severity, including pathways related to lung homeostasis, RAS homeostasis,
and hemostasis. Notably the plasma levels of two proteins implicated in the production of
lung surfactant (SFTPA2 and CTSH; (Buhling et al., 2011; Thorenoor et al., 2018)),
markedly increased with disease severity. Both SFTPA2 and CTSH are synthesized in
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type II pneumocytes (Buhling et al., 2011; Thorenoor et al., 2018), which are primary
targets for SARS-CoV-2 infiltration. As such, these proteins may be early markers of type
II pneumocyte dysfunction, impaired surfactant synthesis and lung damage as SFTPA2
plasma levels have been shown to be elevated in patients suffering from acute respiratory
failure (Doyle et al., 1997). These results are consistent with recent transcriptomics
analyses of lung biopsies showing impaired surfactant production in patients with severe
COVID-19 (Islam and Khan, 2020).
Key proteomic features of the COVID-19 severity model also included two
components of the RAS (ACE2 and MME), a complex hormonal system that regulates
blood pressure, fluid homeostasis as well as pulmonary inflammation (Chappell, 2019).
The involvement of the RAS in the pathogenesis of SARS-CoV-2 infection is wellestablished since the interaction between the viral Spike protein and ACE2 is a primary
mechanism of viral entry into host cells (Mortaz et al., 2020). High ACE2 and MME plasma
levels in severe patients suggest increased shedding from the cell surface which may
result in loss of function of these proteins (Ni et al., 2020). A loss of function of ACE2 and
MME will likely result in a decrease of angiotensin I (Ang-I) and angiotensin II (Ang II)
degradation, which aligns with the multi-organ injuries observed in severe patients (Liu et
al., 2020; Ni et al., 2020). Interestingly, increased plasma ACE2 concentration has
recently been associated with an increased risk for subsequent cardiovascular events in
patients with COVID-19 (Narula et al., 2020). As such, our analysis points at mechanistic
markers of disease severity that may also be implicated in the clinical manifestations of
patients recovering from COVID-19, such as cardiovascular or neurological
complications.
The most informative protein feature in our severity model was MERTK, a
membrane-bound receptor tyrosine kinase that plays a role in immunoregulation,
hemostasis, and endothelial barrier integrity (Cai et al., 2018; Lemke and Silverman,
2020; Li et al., 2019), whose levels in plasma substantially increased with severity. Loss
of endothelial MERTK expression in the lung can result in enhanced permeability and
leukocyte transendothelial migration, thereby aggravating inflammation at the site of
infection and contributing to acute respiratory distress syndrome (Li et al., 2019). In
addition, soluble MERTK can hinder activation of membrane-bound MERTK, resulting in
the inhibition of macrophage-mediated clearance of apoptotic cells and the loss of its
immunosuppressive effect (Cai et al., 2018; Lemke and Silverman, 2020; Sather et al.,
2007). Through its role in both endothelial integrity in the lung and immunoregulation,
dysregulated MERTK could potentially be a central player in the development of severe
COVID-19. In addition, MERTK also plays a role in platelet aggregation (Sather et al.,
2007), and its observed higher plasma levels in patients with the severe disease together
with increased plasma levels of other proteins involved in hemostasis (Hrycek and Cieslik,
2012; Ikeda et al., 2018; Lu et al., 2020a) suggests an increased risk for coagulation and
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thrombosis. Coagulopathy and thrombosis have been observed in many patients that
presented with severe COVID-19 (Gao et al., 2020; Levi et al., 2020).
This study has certain limitations. First, in this cohort, we only assessed peripheral
blood samples of patients affected by COVID-19. It would be of great interest to assess
the local immune and proteome perturbations in parallel by analyzing lung biopsies or
bronchoalveolar lavage fluid to investigate whether the same trends and dampened
immune cell responses are observed locally in the lung as well. Second, this is a singlecenter study with samples collected from patients at Stanford University Medical Center.
Most of the patients that were encountered during the study period had mild symptoms.
Future studies including patients with different ethnicity, socio-economic status, and comorbidities will be important to test the boundary of generalizability of our findings.
Similarly, we recognize that the severity model is independently validated as a highdimensional model. Additional testing in larger and more diverse patient cohorts is
necessary to determine whether individual model features can serve as clinical
biomarkers of disease severity. Finally, this is a cross-sectional study --longitudinal
monitoring of plasma and single-cell proteomic features will give increased insight into
the fluctuation of these features over time and lead to new insights into patients with
COVID-19 “long-hauler” status.
Determining the underlying immune pathogenesis across the spectrum of COVID19 severity remains an important clinical challenge. Our integrated analysis of plasma
and single-cell proteomics in patients with mild, moderate, and severe COVID-19
identified a multivariate model that differentiates COVID-19 severity. The observations
identified by this model contribute clinically relevant insights into the status of patient’s
immune responses during SARS-CoV-2 infection and provide promising severity-specific
biological markers for future validation that may inform decision-making on potential
therapeutic targets for the prevention of disease progression.
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Materials and methods
Study design and sample collection
Design
We conducted this study at Stanford University Medical Center, where the samples were
collected at the Stanford Occupational Health Clinic under an IRB approved protocol
(55689; Protocol Director Dr. Nadeau). We obtained samples from adults with positive
test results for SARS-CoV-2 from analysis of nasopharyngeal swab specimens obtained
at any point from March to June 2020. Follow-up continued through October 5, 2020.
Testing was accomplished using Stanford Health Care clinical laboratory developed
internal testing capability with a quantitative reverse-transcriptase–polymerase-chainreaction (qRT-PCR) assay. Informed consent was obtained from each patient prior to
enrolling in the study or from the patient’s legally authorized representative if the patient
was unable to provide consent. Participants were excluded if they were taking any
experimental medications (i.e. those medications not approved by a regulatory agency
for use in COVID-19). Healthy controls were collected prior to the detection of SARSCoV-2 in the region (historical controls) and were consented using a separate IRBapproved protocol (Protocol Director Dr. Nadeau).
Data sources and clinical definitions
We obtained data from self-reported surveys and from Stanford clinical data electronic
medical record system as per consented participant permission. This database contains
all the clinical data available on all inpatient and outpatient visits to Stanford facilities. The
data obtained included patients’ demographic details, vital signs, laboratory test results,
medication administration data, historical and current medication lists, historical and
current diagnoses, clinical notes, radiological results, biopsy results as appropriate,
historical discharge disposition for previous inpatient hospitalizations, and ventilator use
data. Patient data were collected and definitions and diagnosis of disease were used
according to previously defined criteria (Chen et al., 2020) with the clinical classification
of COVID-19 as followed; Mild disease: mild to no symptoms, and no manifestation of
pneumonia; Moderate disease: fever and respiratory tract symptoms; Severe disease:
hospitalization with respiratory distress.
Phlebotomy and initial blood processing
Blood was analyzed from samples collected from 97 patients with COVID-19 and 40
controls via venipuncture. Anticoagulated blood was processed into peripheral blood
mononuclear cells (PBMC) by density gradient centrifugation using published methods
(Syed et al., 2014). PBMC were stored in 10% DMSO and frozen in liquid nitrogen until
thawing and staining. Plasma was obtained from blood collected in EDTA tubes using
standard procedures and stored at -80°C.
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Mass cytometry analysis of single-cell immune cell responses in PBMC
In vitro PBMC stimulation
Cryopreserved PBMC were quickly thawed, washed two times with supplemented
medium, and rested for 1h at 37°C in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 1% Penicillin-Streptomycin, and 1% L-Glutamine. PBMC were counted
and checked for viability. 0.5-1x106 cells were either stimulated with lipopolysaccharide
(LPS; 1𝜇g/ml) and CL097 (TLR7/8 agonist; 1𝜇g/ml), interleukin-2 (IL-2), IL-4, IL-6 and
interferon-𝛼 (IFN𝛼; all 100 ng/ml), a cocktail of phorbol 12-myristate 13-acetate (PMA),
ionomycin, brefeldin A and monensin (1x; PI cocktail), or left unstimulated for 15 minutes
at 37°C. After stimulation, samples were fixed with Proteomic Stabilizer (SmartTube) and
stored at -80°C until further processing for mass cytometry analysis.
Barcoding and antibody staining
The 42-marker mass cytometry antibody panel included 25 cell surface antibodies and
17 intracellular antibodies recognizing primarily phospho-specific signaling epitopes
(Supplemental data file S2). In brief, following in vitro stimulation, fixed PBMCs were
thawed, reconstituted in cell staining medium, and arranged in a 96-well block.
Subsequent steps were performed using a previously described robotics platform
(Bjornson-Hooper et al., 2019). Sets of 16 samples were barcoded with palladium metal
(Zunder et al., 2015) and pooled into a single well. Pooled barcoded samples were treated
with FC-block (Human TruStain FcX, Biolegend) for 10 minutes then surface antibody
stained for 30 minutes in cell staining medium (PBS with 0.5% BSA and 0.02% sodium
azide). After surface staining, cells were permeabilized in ice-cold 100% methanol,
washed, and stained for 60 minutes with intracellular antibodies in cell staining medium.
Following intracellular staining, cells were washed and resuspended in an iridium
intercalator (Fluidigm) solution containing 1.6% paraformaldehyde. Finally, samples were
washed, resuspended in 1X five-element normalization beads (La, Pr, Tb, Tm, Lu)
(Fluidigm), and analyzed on a freshly cleaned and tuned CyTOF instrument. The resulting
mass cytometry data were bead-normalized across all runs and debarcoded as previously
described (Finck et al., 2013).
Cell frequency, baseline intracellular signaling, and intracellular signaling responses
Mass cytometry data was examined using CellEngine (Primity Bio) to define cell
populations using manual gates and quantify differential expression of signaling markers
in response to stimulation. The gating strategy can be found in supplemental figure S1.
Cell frequencies were expressed as a percentage of gated singlet mononuclear cells
(DNA+CD235a-CD61-CD66-), except for granulocyte frequency which was expressed as
a percentage of singlet leukocytes (DNA+CD235a-CD61-). Phospho-signal intensity was
quantified per single cell for each signaling protein (pSTAT1, pSTAT3, pSTAT4, pSTAT5,
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pSTAT6, pMAPKAPK2, pCREB, pPLCᵧ2, pS6, pERK1/2, pP38, pZAP70/Syk, pTBK1,
p4EBP1, and total IkB𝛼) using an arcsinh transformed value (arcsinh(x/5)) from the
median signal intensity. Endogenous or baseline intracellular signaling activity was
derived from the analysis of unstimulated cells, while intracellular signaling responses to
stimulation were reported as the arcsinh transformed ratio over the baseline signaling,
i.e., the difference in arcsinh transformed signal intensity between the stimulated and
unstimulated condition. For cell subsets in a given sample that had an event count below
20 events, that cell subset and related phospho-signal were excluded from downstream
analysis. A penalization matrix, based on mechanistic immunological knowledge, was
applied to the immune cell response data (Culos et al., 2020; Ghaemi et al., 2019).
Plasma Protein Profiling Using Olink Multiplex Panel
Plasma protein levels were quantified using Olink multiplex proximity extension assay
(PEA) panels (Olink Proteomics; www.olink.com) according to the manufacturer’s
instructions and as described before (Assarsson et al., 2014). The basis of PEA is a dualrecognition immunoassay, where two matched antibodies labeled with unique DNA
oligonucleotides simultaneously bind to a target protein in solution. This brings the two
antibodies into proximity, allowing their DNA oligonucleotides to hybridize, serving as a
template for a DNA polymerase-dependent extension step. This double-stranded DNA
which is unique for a specific antigen will get amplified using P5/P7 Illumina adapters
along with sample indexing, which is quantitatively proportional to the initial concentration
of target protein. These amplified targets will finally get quantified by Next Generation
Sequencing using Illumina Nova Seq 6000 (Illumina Corporation. San Diego, California).
In this study, we have used the Explore 1536 panel which measures 1,472 proteins using
3ul plasma samples, which were treated with 1% Triton X-100 and incubated at room
temperature for 2 hours to inactivate the virus. The raw expression values obtained with
the Olink assay are provided in the arbitrary unit Normalized Protein Expression (NPX),
where high NPX values represent high protein concentration. Values were log2transformed to account for heteroskedasticity. Proteins close to the limit of detection are
flagged in the raw data.
Statistical analysis
Univariate analysis
We used the R environment (http://www.r-project.org/) for statistical analysis. We chose
to apply a ranked regression analysis for each feature relative to the severity of the patient
at the time of sampling. Multiple comparison corrections were performed using the
Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995). For each statistic, we
report both p-values, the associated FDR corrected “q-values,” and regression estimates.
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Multi-omic factor analysis
Multi-omic factor analysis (MOFA) was applied simultaneously across plasma (Olink) and
the single-cell proteomics data (cell frequency, baseline signaling, IFN𝛼/IL-2/IL-4/IL-6
signaling response, LPS/CL097 signaling response, and PI signaling response). MOFA
infers a set of factors that capture both biological and technical sources of variability that
are shared across different datasets. MOFA models were constructed using the six data
layers which were supplied as a list of matrices. We followed the developers’ directions
for model selection and downstream analysis (Argelaguet et al., 2018). Since MOFA is
not guaranteed to find a global optimum, 10 model trials were performed using different
random initializations. For each trial, the number of factors was calculated by requiring at
least 2% variance explained for any single dataset. The model with the highest evidence
lower bound was selected out of these 10 trials (model 6, Figure S2A). The factors
calculated by model 6 of our 10 trials were extracted for downstream analysis. MOFA
enables variance decomposition of the calculated factors and uses a coefficient of
determination (R2) to quantify the fraction of variance explained by each factor for each
dataset, which we examined first to determine how each dataset contributes to each
factor (Figure S2B). Next, we regressed the 17 factors on COVID-19 severity, which was
dummy encoded as follows: Control = 1, Mild = 2, Moderate = 3, Severe = 4. Regression
estimates, 95% confidence intervals, and p-values were examined (Figure S2C). Factors
3, 8, and 10 were significantly associated with COVID-19 severity. To assess the
robustness of factors across model trials, we calculated Pearson correlation coefficients
between every pair of factors across all trials. Factors 3 and 10 were consistently
discovered in all model instances (data not shown). Finally, we visualized our samples
across factors 3 and 10 using a bivariate scatterplot (Figure 1D).
Multivariate analysis and stacked generalization
For the multivariate analysis, a LASSO model was trained independently on each omics
dataset independently. For a matrix X of all biological features from a given -omic data
set, and a vector of disease severity Y, the LASSO algorithm (Tibshirani, 1996) calculates
coefficients β to minimize the error term L(β)=||Y−Xβ||2. The L1 regularization is used to
increase model sparsity for the sake of biological interpretation and model robustness.
Once a LASSO model is trained for each omics modality (individual model performance
Table S2), the multi-omics analysis can be carried out by performing stacked
generalization (Ghaemi et al., 2019) on the new representation of the data by using the
outputs of the previous layer of models as predictors with the constraint that their
participation should be a non-negative coefficient. Particularly, a LASSO model is first
constructed on each omics modality, then all estimations of disease severity are used as
predictors for a second-layer constrained regression model. Intrinsically, this is equivalent
to a weighted average of the individual models with the coefficients of the LASSO model
as desired weights.
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Cross-validation
An underlying assumption of the LASSO algorithm is statistical independence between
all observations. In this analysis, subjects are independent, and, in this regime, a model
is trained on all available samples from all subjects. However, at each iteration, one
sample is kept for independent validation. The reported results are exclusively based on
the blinded subject. For stacked generalization, a two-layer cross-validation strategy was
implemented where the inner layer selects the best values of λ and reports the
intermediate prediction. Then, the outer layer optimizes the constrained regression of all
predictors for the stacked generalization step. Cross-validation folds are carefully
synchronized between the individual models from each omics.
Bootstrap analysis for feature selection
For each omics dataset, we performed a bootstrap analysis where we repeat a
bootstrapping procedure on the dataset and train a cross-validated model. At each
iteration, we keep the non-zero coefficients selected by the LASSO procedure on the
bootstrapped dataset and we repeat the procedure 1,000 times (Bach, 2008; Chatterjee
and Lahiri, 2011). We report the frequency of selection of the features as well as their
median coefficient in all the bootstrap models. This method selected 44 frequency, 599
baseline, 536 PI-response, 492 IFN𝛼/IL-2/IL-4/IL-6, and 783 proteome features that were
informative in at least one iteration of the bootstrap procedure (see supplemental file
S1). To assess the relative importance of each feature to the model, we ranked features
in each data layer based on their frequency of selection.
Correlation network
The features are visualized using a correlation graph structure to identify correlated
feature populations. Each biological feature is denoted by a node whose size is
dependent on the -𝑙𝑜𝑔10 of p-value of correlation with disease severity (Spearman). The
correlation network between the features is represented by an edge where the width of
the edges is proportional to the Spearman p-value of the correlation between a pair of
nodes on a log 10 scale. The graph is visualized using the t-SNE layout.
Confounder analysis
A linear regression analysis was used as a statistical method to exclude the likelihood
that certain clinical or demographic variables confounded the predictive accuracy of the
severity model.
Multi-class receiver operating characteristics (AUC)
To characterize our predictions' separability in a multi-class setting, we used a combined
metric of the area under the receiver operating curve (AUC) in both the training and
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validation model. This metric for multi-class analysis uses every combination of labels in
one-to-one comparisons. Every subset of predictions on a pair of classes is considered
independently, and the AUC is calculated for each specific pair. Once all the subset AUCs
are computed, the generalizable AUC combines them, taking their mean across all
comparisons, to give the multi-class model's overall performance (Hand and Till, 2001).
Plasma proteomic pathway identifier
To obtain pathway information of selected proteome features, we utilized Reactome
(www.reactome.org), a web-based resource for identifying biological pathways, in which
we used the list of the 10% bootstrap-selected proteins as an input. Reactome provided
a list of pathways, identified by a Reactome gene set identifier, which we assessed for
the proteins part of specific pathways.
Data availability
Raw data, processed data, and source code for the reproduction of the results will be
made publicly available on Flowrepository (ID: FR-FCM-Z3G5) and Github.
Supplemental material
Supplemental file S1 lists the features informative of the severity model as selected by
the bootstrap procedure (xlsx-file). Supplemental file S2 contains the mass cytometry
antibody panel. Figure S1 shows the manual gating strategy used to identify innate and
adaptive immune cells. Figure S2 shows the MOFA analysis to identify shared sources
of variability across the plasma and single-cell proteomics data. Figure S3 displays the
frequency of plasmablasts, and the immune cell signaling features at baseline and after
stimulation with inflammatory agents that are informative to the severity model. Figure S4
shows plasma protein level features that are informative to the severity model. Figure S5
shows plasma protein level features that are part of neutrophil degranulation and
hemostasis, and informative to the severity model. Table S1 contains the model
performance of the individual data layers, and the contribution of the individual data layers
to the severity model (weighted average of model coefficients). Table S2 shows how well
the severity classifies each patient group from the other. Table S3 contains the results of
the confounder analysis.
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Figure S1. Hierarchical manual gating strategy used for mass cytometry analyses.
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Figure S2. Multi-omic factor analysis (MOFA) identifies shared sources of variability across singlecell cytometry and proteomic data that are associated with COVID-19 severity
A Ten MOFA models were constructed with different random initializations. Shown are the number of
factors calculated for each trial, and colored by the corresponding evidence lower bound (ELBO). B
Portion of variance explained (R 2) for each factor and for each dataset. IFN/IL = IFNα/IL-2/IL-4/IL-6 C
Association of MOFA factors with COVID-19 severity (encoded as Control = 1, Mild = 2, Moderate = 3,
Severe = 4) was performed with linear regression analysis. Estimates, 95% confidence intervals, and pvalues are shown (significant p-values highlighted red).
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Figure S3 – Frequency and immune cell signaling response features
Boxplots showing plasmablast frequency, immune cell signaling responses at baseline (reported as
arcsinh transformed values), and signaling response after stimulation with inflammatory agents (reported
as arcsinh transformed ratio over the baseline signaling response; see methods). A Plasmablast
frequency (CD38+IgM-CD19+). B Baseline immune cell signaling response. C immune cell signaling
response to PI stimulation, and D response to IFNα/IL-2/IL-4/IL-6 stimulation (IFN/IL) of features
informative in the COVID-19 severity model. Boxplots classified by disease severity and including
correlation of the feature with disease severity (Spearman coefficient). Tmem = memory T cell; Teff =
effector T cell.
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Figure S4 - Plasma proteomic features informative to the model
Boxplots showing plasma protein levels of features that are informative in the COVID-19 severity model.
Boxplots are classified by disease severity and include the correlation of the feature with disease severity
(Spearman coefficient). ACE2 = angiotensin-converting enzyme 2; MME = neprilysin; SFTPA2 =
surfactant-associated protein A2; CTSH = cathepsin H.
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Figure S5 – Informative plasma proteomic features involved in neutrophil degranulation and
hemostasis
Boxplots showing plasma protein levels of features that are informative in the COVID-19 severity model
and that are part of A neutrophil degranulation (Reactome gene set identifier R-HSA-6798695.2) and B
hemostasis (Reactome gene set identifier R-HSA-109582). Boxplots are classified by disease severity
and include the correlation of the feature with disease severity (Spearman coefficient). GGH = Gammaglutamyl hydrolase; FCN2 = Ficolin-2; AZU1 = Azurocidin; FUCA1 = Tissue alpha-L-fucosidase; AOC1 =
Amiloride-sensitive amine oxidase [copper-containing]; PADI2 = Protein-arginine deiminase type-2; VAT1
= Synaptic vesicle membrane protein VAT-1 homolog; SIGLEC9 = Sialic acid-binding Ig-like lectin 9;
CTSB = Cathepsin B; WFDC2 = WAP four-disulfide core domain protein 2; SDC1 = syndecan-1; COL1A1
= Collagen alpha-1(I) chain; ACTN4 = Alpha-actinin-4; ITIH3 = Inter-alpha-trypsin inhibitor heavy chain
H3; CEACAM5 = Carcinoembryonic antigen-related cell adhesion molecule 5; L1CAM = Neural cell
adhesion molecule L1; ANXA5 = Annexin A5; TP53 = Cellular tumor antigen p53.
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training
AUC

validation
AUC

1vs2

0.71

0.6071

1vs3

0.85

0.7697

1vs4

0.90

0.9238

2vs3

0.71

0.6623

2vs4

0.82

0.8571

3vs4

0.81

0.8182

Table S2 – AUC of individual ROC analyses for performance of severity model to classify
severity
AUC shows how well the severity model is able to classify each patient group from the other. 1 = control,
2 = mild, 3 = moderate, and 4 = severe. Results related to Figure 2 D-E
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Variable

Estimate

Std.Error

t

value

Pr(>|t|)

Prediction model

0.441365

0.128161

3.444

0.00177

***

Days between
symptom onset and
sample collection

-0.005135

0.006448

-0.796

0.43225

NS

Age

0.010871

0.006316

1.721

0.09589

NS

SexM

-0.306411

0.199897

-1.533

0.13615

NS

BMI

0.050989

0.016994

3.000

0.00550

**

Table S3 – Confounder analysis
None of the potentially confounding variables significantly influenced the COVID-19 severity model.
Related to Figure 2. SexM = male sex. BMI = body mass index. NS = not significant

